aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Palvella Therapeutics, founded in Pennsylvania, is a biopharmaceutical company committed to developing therapies for rare and genetic diseases. Their core mission is to improve the lives of patients suffering from these conditions through innovative treatments. The company focuses on a range of rare diseases, including Microcystic Lymphatic Malformations and Gorlin Syndrome, with a robust pipeline that includes PTX-014 among other clinical programs.
Notable figures associated with Palvella Therapeutics include experienced leaders in the biopharmaceutical industry and a board comprising experts in rare disease research. The company has garnered significant investment from reputable venture capital firms, bolstering its research and development efforts. Key achievements include advancing multiple therapies into clinical trials, demonstrating their potential impact on the treatment landscape for rare genetic disorders. Palvella Therapeutics continues to make strides in addressing unmet medical needs, significantly impacting patient care and therapeutic options.
Operating Status
Acquired
Main Product(s)
Therapeutics, Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Palvella Therapeutics founded?
Palvella Therapeutics was founded in 2015.
Where is Palvella Therapeutics's headquarters located?
Palvella Therapeutics's headquarters is located in Wayne, PA, US.
When was Palvella Therapeutics's last funding round?
Palvella Therapeutics's most recent funding round was for $37.7M (USD) in January 2023.
How many employees does Palvella Therapeutics have?
Palvella Therapeutics has 39 employees as of Feb 5, 2024.
How much has Palvella Therapeutics raised to-date?
As of July 05, 2023, Palvella Therapeutics has raised a total of $106.8M (USD) since Jan 5, 2023.
Add Comparison
Total Raised to Date
$106.8M
USD
Last Update Jan 5, 2023
Last Deal Details
$37.7M
USD
Jan 5, 2023
Series D
Total Employees Over Time
39
As of Feb 2024
Palvella Therapeutics Address
125 Strafford Avenue
Suite # 360
Wayne,
Pennsylvania
19087
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts